19 million people under Latin America's most OECD-mature regulatory framework, the world's highest gallbladder cancer incidence, Clínica Alemana's European-standard research platform, Pacific Alliance multi-country network access, and per-patient costs competitive with any Southern Cone peer economy.
Chile is a unitary republic of approximately 19 million people occupying one of the world's most geographically extreme nations; a narrow ribbon 4,270 km long and averaging only 177 km wide along the Pacific coast of South America, bordered by Peru to the north, Bolivia to the northeast, and Argentina to the east across the Andes. This extraordinary elongation creates radically different disease and demographic profiles across its length: the hyper-arid Atacama Desert in the north, a Mediterranean-climate agricultural heartland in the centre, temperate rainforests in the Lakes Region, and Patagonian steppe in the far south. Santiago; the capital and primate city; concentrates approximately 40% of the national population in a single metropolitan area (~8 million) and virtually all of Chile's clinical research activity, with a hospital infrastructure spanning JCI-accredited private institutions (Clínica Alemana, Hospital UC Christus, Clínica Las Condes) and the major public academic network (Hospital Clínico Universidad de Chile, Hospital San Juan de Dios, Hospital Barros Luco-Trudeau, Hospital Sótero del Río). Valparaíso; Chile's principal Pacific port and a UNESCO World Heritage city ~120 km from Santiago; provides the second research corridor through Hospital Gustavo Fricke and Hospital Carlos Van Buren. Concepción in the Biobío Region anchors the southern corridor and serves as the gateway to Chile's Mapuche-majority Araucanía region, where gallbladder cancer incidence reaches its highest recorded rates globally. Chile has been an OECD member since 2010; one of Latin America's earliest accessions; and is a founding member of the Pacific Alliance alongside Colombia, Mexico, and Peru.
Clinical trials are regulated by ANAMED (Agencia Nacional de Medicamentos); a dedicated pharmaceutical regulatory agency established in 2020, separating medicines and devices regulation from the ISP's broader public health mandate in a reform designed to create a focused, internationally benchmarked regulatory environment. ANAMED operates under the ICH GCP E6(R2) framework; ethics review is managed through institutional Comités Éticos Científicos (CECs) accredited by CONEIS under ANID (Chile's national research funding agency). Chile's dual healthcare financing system; FONASA (public insurance, covering ~77% of the population) and ISAPREs (private insurers, covering ~18%); achieves combined health insurance coverage of approximately 95% of the Chilean population, one of Latin America's highest rates, creating structured patient identification pathways across both the public and private hospital sectors. Chile's 15+ years of OECD membership means its research ethics standards, data quality systems, and pharmaceutical regulatory practices have been aligning with international benchmarks for longer than any other Latin American country except Mexico.
Chile's population reflects centuries of Spanish colonisation overlaid on a Mapuche indigenous substrate: approximately 65% mestizo (mixed Spanish European and Amerindian), 20% White (predominantly Spanish heritage, with German communities in the Lakes Region, Croatian communities in Punta Arenas, and Palestinian communities in Santiago), 9% Mapuche; Chile's largest indigenous people and the most pharmacogenomically studied indigenous group in South America; and smaller Aymara, Rapa Nui, and other indigenous populations. The Mapuche are of particular pharmacogenomic significance: studies have documented specific CYP2C19 variant frequencies in Mapuche-ancestry individuals that differ meaningfully from European populations, affecting metabolism of proton-pump inhibitors, antiplatelet agents, and antidepressants; more consequentially, the Mapuche genetic heritage predisposes to lithogenic bile; a heritable tendency toward supersaturated biliary secretions that crystallise into gallstones at dramatically elevated rates; which over time drives chronic cholecystitis and malignant transformation of the gallbladder epithelium. Southern Chile carries a notable German-heritage community in the Lakes Region (Osorno, Puerto Varas, Valdivia, Puerto Montt); descendants of 19th-century immigrants; whose connection to German medicine is reflected in Santiago's Clínica Alemana and its affiliated Universidad del Desarrollo Faculty of Medicine. National literacy exceeds 98%; English proficiency is strong at major academic research institutions; Spanish is the research working language.
Chile's disease profile increasingly mirrors high-income Southern European countries, but retains epidemiological features of global scientific importance. Cardiovascular disease is the leading cause of death (~28% of mortality), with hypertension prevalent in ~28% of adults and ischaemic heart disease growing rapidly. Obesity affects approximately 34% of Chilean adults; among Latin America's highest rates; driving rising Type 2 diabetes (~12–14% of adults), NAFLD, and metabolic syndrome. Cancer is the second leading cause of death; Chile's most globally distinctive burden is gallbladder adenocarcinoma, whose incidence rates; particularly among women in the Biobío, Araucanía, and Los Lagos regions; are the highest recorded anywhere in the world with a functional oncology research infrastructure. Gastric cancer rates remain elevated above global averages, contributing to Chile's broader GI oncology burden. Mental health disorders carry significant burden; depression and anxiety are well-diagnosed and treatment-seeking in urban Chile; and respiratory disease, chronic kidney disease, and rheumatological conditions complete an NCD profile of growing complexity.
Gallbladder cancer; Chile's globally unique research niche, and the world's most concentrated biliary oncology research platform: Chile records the world's highest national incidence of gallbladder adenocarcinoma among countries with the healthcare infrastructure to conduct rigorous clinical research. Chilean women experience gallbladder cancer at rates of approximately 10–15 per 100,000 per year; six to eight times the global average; with rates in Mapuche-majority zones of the Araucanía and Los Lagos regions reaching the highest documented anywhere. The mechanism is well-characterised: the Mapuche genetic heritage predisposes to lithogenic bile whose supersaturation drives gallstone disease in an estimated 25–30% of Chilean adult women (up to 50% in Mapuche-ancestry women in endemic areas), and chronic cholelithiasis drives progressive cholecystitis and malignant transformation through the cholesterol stone → chronic inflammation → dysplasia → adenocarcinoma cascade. The research consequences are profound: Chile has the world's largest population of gallbladder cancer patients in a country with OECD-aligned clinical trial infrastructure. Surgical oncology and hepatopancreatobiliary departments at Hospital Sótero del Río, Hospital Clínico Universidad de Chile, and Hospital UC Christus have produced Chile's internationally published GI oncology research for decades. The estimated 1.5–2 million Chilean women with active gallstone disease constitutes the world's largest accessible pre-malignant biliary disease population for chemoprevention and lithogenesis intervention research. No approved targeted therapy exists for gallbladder cancer beyond platinum-based chemotherapy; the treatment landscape is essentially undeveloped; and for any sponsor developing FGFR, HER2, IDH1, or immune checkpoint-targeted therapies for biliary tract cancers, Chile's biliary oncology infrastructure is the necessary global clinical development anchor.
Chile's research proposition is built on quality, regulatory maturity, and a gallbladder cancer niche that makes it the world's only viable platform for biliary oncology programs at scale; all within LATAM's longest-established OECD-aligned regulatory environment outside Mexico, near-universal health insurance coverage creating structured patient pathways, and a Santiago private hospital cluster whose research standards rival European academic centres at emerging market cost levels.
ANAMED; dedicated pharmaceutical regulatory agency established 2020, separating medicines regulation from ISP; ICH GCP E6(R2)-aligned framework; CONEIS/ANID national bioethics oversight with accredited institutional CEC ethics committees; OECD member since 2010; Latin America's 2nd longest-tenured regulatory alignment after Mexico; Pacific Alliance pharmaceutical harmonisation integrating Chile with Colombia, Mexico, and Peru; ANAMED review timelines improving toward the 90; 120 day range for multinational Phase III submissions.
Per-patient and operational costs substantially below US and EU equivalents; CLP-denominated operational expenses competitive for USD and EUR-budgeted programs; 95% health insurance coverage (FONASA + ISAPREs) reduces pre-screening overhead through structured insurance-based patient pathways; investigator fees and site overhead significantly lower than European sites of comparable research quality; Pacific Alliance regional programme coordination reduces per-country duplication costs when Chile anchors Colombia-Peru-Mexico multi-country Phase III designs.
19M people with 95% health insurance coverage for structured enrollment; world's highest gallbladder cancer incidence; the largest biliary tract cancer research population of any OECD-aligned country; estimated 1.5–2M Chilean women with active gallstone disease creating the world's largest pre-malignant biliary disease pool; elevated gastric cancer rates extending GI oncology breadth; Mapuche CYP2C19 and biliary metabolism variants for indigenous pharmacogenomics; large treatment-naïve cardiovascular, obesity, NAFLD, and metabolic disease pools; well-educated, treatment-seeking urban population with high clinical trial compliance.
Hospital UC Christus; PUC's internationally connected flagship academic hospital; Clínica Alemana; German-heritage private hospital with European-standard GCP quality and Universidad del Desarrollo affiliation; Clínica Las Condes; JCI-accredited private research hospital; Hospital Clínico Universidad de Chile; premier public academic anchor; Hospital Sótero del Río and Hospital San Juan de Dios for gallbladder and GI oncology surgical research; OECD-mature national health data registries (DEIS) supporting trial feasibility; established IQVIA, ICON, and Syneos operations in Santiago.
GI oncology; and gallbladder cancer specifically; is Chile's most globally distinctive research pillar: the combination of the world's highest gallbladder cancer incidence, the world's largest gallstone disease population accessible through OECD-aligned research infrastructure, and hepatopancreatobiliary surgical oncology programmes at Hospital UC Christus, Hospital Clínico Universidad de Chile, and Hospital Sótero del Río with decades of published biliary cancer research creates a Phase II–III platform for biliary tract cancers (gallbladder adenocarcinoma, cholangiocarcinoma, and ampullary carcinoma) that is unmatched anywhere. Gastric cancer; Chile's second GI oncology pillar, with elevated incidence rates and large treatment-naïve public hospital patient pools; extends the country's GI oncology depth beyond the biliary niche. Cardiovascular medicine is the second major commercial pillar, the leading cause of Chilean mortality and the focus of well-established research programmes at Clínica Alemana, Hospital UC Christus, and the Universidad de Chile's cardiology department. Metabolic disease; driven by Chile's extraordinary obesity rates (approximately 34% of adults obese, among Latin America's highest) and its consequent Type 2 diabetes, NAFLD, and metabolic syndrome burden; is the third pillar, with FONASA insurance pathways creating structured access to large treatment-naïve metabolic disease populations. CNS and mental health research has grown steadily, anchored by Chile's relatively high rates of urban mental health diagnosis and treatment-seeking. Respiratory medicine, rheumatology, women's health, and rare disease programmes complete a therapeutic portfolio whose breadth reflects Chile's OECD-equivalent healthcare maturity.
Santiago dominates Chilean clinical research; concentrating approximately 40% of the national population within a single metropolitan area and housing every major research institution, from the JCI-accredited private hospitals (Clínica Alemana, Hospital UC Christus, Clínica Las Condes) to the flagship public academic hospitals of the Universidad de Chile system. Valparaíso and Concepción provide the two secondary research corridors, the latter particularly important for gallbladder cancer and Mapuche population research given proximity to Chile's highest-incidence zones in the Araucanía and Los Lagos regions further south.
| # | Site | City | Notes |
|---|---|---|---|
| 01 | Hospital UC Christus (Pontificia Universidad Católica de Chile) | Santiago | Chile's most internationally connected academic research hospital; the clinical flagship of the Pontificia Universidad Católica de Chile, one of Latin America's most prestigious universities; formed by the integration of Hospital Clínico UC and Clínica UC San Carlos de Apoquindo; Phase I–IV commercial trial portfolio across oncology, cardiovascular, metabolic disease, gastroenterology, neurology, and rheumatology; its hepatopancreatobiliary surgical oncology programme has been central to Chile's gallbladder cancer clinical research output, with internationally published collaborative research on cholangiocarcinoma and gallbladder adenocarcinoma surgical outcomes and systemic therapy programs among the most cited in the Southern Hemisphere. |
| 02 | Clínica Alemana de Santiago | Santiago | Chile's most distinctively international private research hospital; founded in 1938 by the German-Chilean community and affiliated with the Universidad del Desarrollo Faculty of Medicine; whose clinical research department operates to GCP standards and documentation quality comparable to leading German and Swiss private research hospitals; Phase I–IV across oncology, cardiovascular, metabolic disease, respiratory, and CNS indications; consistently among Chile's most active commercial Phase II–III trial sites by trial count and international pharmaceutical company partnership breadth; Clínica Alemana represents the most direct embodiment of European medical research culture within the Chilean healthcare system. |
| 03 | Hospital Clínico Universidad de Chile "Dr. José Joaquín Aguirre" | Santiago | Chile's primary public academic teaching hospital; affiliated with the Universidad de Chile, the country's oldest and most research-productive public university; and the public academic anchor of Santiago's clinical trial network; Phase I–IV across haematology, oncology, cardiovascular, metabolic disease, infectious disease, and transplantation; its hepatology and hepatopancreatobiliary surgery departments have sustained decades of gallbladder cancer, gastric cancer, and liver disease research; its large and socioeconomically diverse patient catchment creates research access to treatment-naïve disease populations substantially larger than those available through the private hospital network alone. |
| 04 | Clínica Las Condes | Santiago | One of Santiago's most prestigious private hospitals; JCI-accredited and consistently ranked among Chile's best; with an active Phase II–IV commercial trial portfolio across oncology, cardiovascular, endocrinology, gastroenterology, and neurology; its Research Centre maintains established commercial pharmaceutical company relationships and a clinical research team whose documentation and protocol compliance standards are the benchmark for Chilean private hospital research; its Las Condes patient catchment provides access to Santiago's upper-income professional population whose health literacy and trial compliance rates create enrollment patterns comparable to Western European private clinical research populations. |
| 05 | Hospital Sótero del Río | Santiago | A major FONASA public hospital in Puente Alto; Santiago's most populous municipality, with substantial mestizo and Mapuche-heritage working-class demographics; and one of Chile's most important sites for gallbladder cancer and biliary disease research; its hepatopancreatobiliary surgery service manages one of Chile's largest gallbladder cancer surgical caseloads, reflecting its catchment from southern Santiago where Mapuche-ancestry migration has concentrated over decades; Phase II–III activity across GI oncology (particularly biliary and gastric cancers), cardiovascular, and general surgery; a critical site for sponsors requiring gallbladder cancer enrollment volumes achievable only through a high-volume FONASA oncology surgery unit with the patient demographics of southern Santiago. |
| 06 | Hospital San Juan de Dios | Santiago | One of Santiago's largest and most historically established public hospitals; serving western and central Santiago; and an active Phase II–III research site across haematology, oncology, infectious disease, and internal medicine; Universidad de Chile Faculty of Medicine affiliate; its haematology department has been among Chile's most active for haematological malignancy clinical trials, with an established international cooperative oncology group connection and a patient catchment including large treatment-naïve pools of lymphoma, leukaemia, and myeloma patients from FONASA's western Santiago coverage zone. |
| 07 | Hospital Barros Luco-Trudeau | Santiago | A major FONASA general hospital in southern Santiago affiliated with the Universidad de Chile Faculty of Medicine, with Phase II–III research activity across cardiovascular disease, oncology, endocrinology, and internal medicine; one of Chile's highest-volume public oncology treatment centres, providing research access to a large treatment-naïve southern Santiago population whose demographics; predominantly mestizo and working-class, with significant Mapuche ancestry; are most relevant for gallbladder cancer and GI oncology research; its endocrinology and metabolic disease departments have been active in Type 2 diabetes and obesity-linked NAFLD clinical research. |
| 08 | Hospital Gustavo Fricke | Viña del Mar | The primary academic teaching hospital of the Universidad de Valparaíso Faculty of Medicine and the most research-active institution in the Valparaíso Region; Phase II–III across oncology, cardiovascular, metabolic disease, and internal medicine; its patient catchment from the greater Valparaíso metropolitan area of approximately 1 million people provides access to the Central Chilean coast's population whose maritime occupational exposures and disease profile complement the inland Santiago catchment; its position as the Valparaíso Region's university reference hospital makes it the essential site for sponsors requiring research coverage extending beyond Santiago. |
| 09 | Hospital Carlos Van Buren | Valparaíso | Valparaíso city's major public general hospital and a significant Phase II–III research site on the Pacific coast; internal medicine, infectious disease, cardiovascular, and oncology trial activity; named after a 19th-century German-Chilean surgeon reflecting Valparaíso's historically cosmopolitan port character, it serves the city of Valparaíso proper (~300,000 people) whose historic working-class port population presents a distinct socioeconomic and occupational health research demographic complementary to Hospital Gustavo Fricke's Viña del Mar catchment. |
| 10 | Hospital Regional de Concepción "Dr. Guillermo Grant Benavente" | Concepción | Concepción's major public reference hospital and the primary research institution for the Biobío Region; Chile's most populous region outside Santiago (~2 million people); affiliated with the Universidad de Concepción Faculty of Medicine; Phase II–III across oncology (gastric and gallbladder cancer reflecting Biobío's elevated GI burden), cardiovascular, respiratory, and internal medicine; its geographic position at the gateway to the Araucanía Region; Chile's most Mapuche-majority and highest gallbladder cancer incidence zone; creates a clinical catchment extending into the indigenous population corridors south of the Biobío River; essential for sponsors needing gallbladder cancer enrollment volumes beyond what Santiago hospitals can achieve. |
| 11 | Hospital Las Higueras | Talcahuano | A major public hospital in Talcahuano; the industrial port city adjacent to Concepción; and an active Phase II–III research site in the Biobío Region's twin-city corridor; oncology, cardiovascular, and internal medicine trial activity; serves the Talcahuano-Concepción industrial population whose occupational exposure profiles and dietary patterns create specific research populations relevant for cardiovascular risk and GI oncology; its complementary position within the Concepción metropolitan area pairs effectively with Hospital Regional de Concepción's university hospital capacity for sponsors designing full Biobío Region Phase III coverage. |
| 12 | Hospital Base de Valdivia (Universidad Austral de Chile) | Valdivia | Southern Chile's premier academic research hospital; affiliated with the Universidad Austral de Chile, whose Faculty of Medicine and Institute of Clinical Pharmacology have built internationally connected research programmes in pharmacology, gastroenterology, and infectious disease; Phase II–III across pharmacology, GI disease, hepatology, and internal medicine; Valdivia's position in southern Chile's Lakes Region; where the German-Chilean community has historical influence and Mapuche-ancestry populations in the adjacent Araucanía transition zone create a unique demographic; makes Hospital Base de Valdivia an important research window into southern Chile's most genetically distinct populations; the Universidad Austral's pharmacology institute has participated in international studies with relevance to CYP2C19 variant populations in Chilean indigenous communities. |
Chile's most internationally connected academic research hospital; the clinical flagship of the Pontificia Universidad Católica de Chile, one of Latin America's most prestigious universities; formed by the integration of Hospital Clínico UC and Clínica UC San Carlos de Apoquindo; Phase I–IV commercial trial portfolio across oncology, cardiovascular, metabolic disease, gastroenterology, neurology, and rheumatology; its hepatopancreatobiliary surgical oncology programme has been central to Chile's gallbladder cancer clinical research output, with internationally published collaborative research on cholangiocarcinoma and gallbladder adenocarcinoma surgical outcomes and systemic therapy programs among the most cited in the Southern Hemisphere.
Chile's most distinctively international private research hospital; founded in 1938 by the German-Chilean community and affiliated with the Universidad del Desarrollo Faculty of Medicine; whose clinical research department operates to GCP standards and documentation quality comparable to leading German and Swiss private research hospitals; Phase I–IV across oncology, cardiovascular, metabolic disease, respiratory, and CNS indications; consistently among Chile's most active commercial Phase II–III trial sites by trial count and international pharmaceutical company partnership breadth; Clínica Alemana represents the most direct embodiment of European medical research culture within the Chilean healthcare system.
Chile's primary public academic teaching hospital; affiliated with the Universidad de Chile, the country's oldest and most research-productive public university; and the public academic anchor of Santiago's clinical trial network; Phase I–IV across haematology, oncology, cardiovascular, metabolic disease, infectious disease, and transplantation; its hepatology and hepatopancreatobiliary surgery departments have sustained decades of gallbladder cancer, gastric cancer, and liver disease research; its large and socioeconomically diverse patient catchment creates research access to treatment-naïve disease populations substantially larger than those available through the private hospital network alone.
One of Santiago's most prestigious private hospitals; JCI-accredited and consistently ranked among Chile's best; with an active Phase II–IV commercial trial portfolio across oncology, cardiovascular, endocrinology, gastroenterology, and neurology; its Research Centre maintains established commercial pharmaceutical company relationships and a clinical research team whose documentation and protocol compliance standards are the benchmark for Chilean private hospital research; its Las Condes patient catchment provides access to Santiago's upper-income professional population whose health literacy and trial compliance rates create enrollment patterns comparable to Western European private clinical research populations.
A major FONASA public hospital in Puente Alto; Santiago's most populous municipality, with substantial mestizo and Mapuche-heritage working-class demographics; and one of Chile's most important sites for gallbladder cancer and biliary disease research; its hepatopancreatobiliary surgery service manages one of Chile's largest gallbladder cancer surgical caseloads, reflecting its catchment from southern Santiago where Mapuche-ancestry migration has concentrated over decades; Phase II–III activity across GI oncology (particularly biliary and gastric cancers), cardiovascular, and general surgery; a critical site for sponsors requiring gallbladder cancer enrollment volumes achievable only through a high-volume FONASA oncology surgery unit with the patient demographics of southern Santiago.
One of Santiago's largest and most historically established public hospitals; serving western and central Santiago; and an active Phase II–III research site across haematology, oncology, infectious disease, and internal medicine; Universidad de Chile Faculty of Medicine affiliate; its haematology department has been among Chile's most active for haematological malignancy clinical trials, with an established international cooperative oncology group connection and a patient catchment including large treatment-naïve pools of lymphoma, leukaemia, and myeloma patients from FONASA's western Santiago coverage zone.
A major FONASA general hospital in southern Santiago affiliated with the Universidad de Chile Faculty of Medicine, with Phase II–III research activity across cardiovascular disease, oncology, endocrinology, and internal medicine; one of Chile's highest-volume public oncology treatment centres, providing research access to a large treatment-naïve southern Santiago population whose demographics; predominantly mestizo and working-class, with significant Mapuche ancestry; are most relevant for gallbladder cancer and GI oncology research; its endocrinology and metabolic disease departments have been active in Type 2 diabetes and obesity-linked NAFLD clinical research.
The primary academic teaching hospital of the Universidad de Valparaíso Faculty of Medicine and the most research-active institution in the Valparaíso Region; Phase II–III across oncology, cardiovascular, metabolic disease, and internal medicine; its patient catchment from the greater Valparaíso metropolitan area of approximately 1 million people provides access to the Central Chilean coast's population whose maritime occupational exposures and disease profile complement the inland Santiago catchment; its position as the Valparaíso Region's university reference hospital makes it the essential site for sponsors requiring research coverage extending beyond Santiago.
Valparaíso city's major public general hospital and a significant Phase II–III research site on the Pacific coast; internal medicine, infectious disease, cardiovascular, and oncology trial activity; named after a 19th-century German-Chilean surgeon reflecting Valparaíso's historically cosmopolitan port character, it serves the city of Valparaíso proper (~300,000 people) whose historic working-class port population presents a distinct socioeconomic and occupational health research demographic complementary to Hospital Gustavo Fricke's Viña del Mar catchment.
Concepción's major public reference hospital and the primary research institution for the Biobío Region; Chile's most populous region outside Santiago (~2 million people); affiliated with the Universidad de Concepción Faculty of Medicine; Phase II–III across oncology (gastric and gallbladder cancer reflecting Biobío's elevated GI burden), cardiovascular, respiratory, and internal medicine; its geographic position at the gateway to the Araucanía Region; Chile's most Mapuche-majority and highest gallbladder cancer incidence zone; creates a clinical catchment extending into the indigenous population corridors south of the Biobío River; essential for sponsors needing gallbladder cancer enrollment volumes beyond what Santiago hospitals can achieve.
A major public hospital in Talcahuano; the industrial port city adjacent to Concepción; and an active Phase II–III research site in the Biobío Region's twin-city corridor; oncology, cardiovascular, and internal medicine trial activity; serves the Talcahuano-Concepción industrial population whose occupational exposure profiles and dietary patterns create specific research populations relevant for cardiovascular risk and GI oncology; its complementary position within the Concepción metropolitan area pairs effectively with Hospital Regional de Concepción's university hospital capacity for sponsors designing full Biobío Region Phase III coverage.
Southern Chile's premier academic research hospital; affiliated with the Universidad Austral de Chile, whose Faculty of Medicine and Institute of Clinical Pharmacology have built internationally connected research programmes in pharmacology, gastroenterology, and infectious disease; Phase II–III across pharmacology, GI disease, hepatology, and internal medicine; Valdivia's position in southern Chile's Lakes Region; where the German-Chilean community has historical influence and Mapuche-ancestry populations in the adjacent Araucanía transition zone create a unique demographic; makes Hospital Base de Valdivia an important research window into southern Chile's most genetically distinct populations; the Universidad Austral's pharmacology institute has participated in international studies with relevance to CYP2C19 variant populations in Chilean indigenous communities.
These are the primary regulatory, academic, and industry bodies shaping Chile's clinical research ecosystem.
Chile's dedicated pharmaceutical regulatory agency established in 2020, separating medicines and medical device regulation from the ISP's broader public health mandate; clinical trial regulation under ANAMED incorporates ICH GCP E6(R2) principles; ANAMED's dedicated clinical trial review division is progressively improving timelines and pharmaceutical assessment capacity as part of Chile's OECD health standards alignment; all sponsors must obtain ANAMED authorisation alongside institutional CEC ethics approval, with combined timelines targeting the 90–120 day range for well-prepared multinational Phase III submissions.
Chile's national research funding agency (successor to CONICYT), overseeing CONEIS; the national body that accredits Chile's institutional Comités Éticos Científicos and sets national research ethics review standards; ANID provides competitive research funding across biomedical sciences, clinical pharmacology, oncology, and pharmacogenomics through FONDECYT grants and Millennium Science Initiative institutes; its international cooperation agreements with NIH, the European Research Council, and BBSRC embed Chilean investigators in globally connected research networks, creating the academic partnerships through which multinational Phase II–III commercial programmes activate Chilean site networks.
Chile's Ministry of Health oversees the FONASA public health insurance system covering approximately 77% of Chileans; the primary patient identification infrastructure for commercially sponsored clinical trials in Chile's public academic hospitals; the Ministry's national cancer strategy and cardiovascular disease programs set the public health priorities that align with Chile's deepest clinical research areas; FONASA's hospital network provides the patient pathway infrastructure through which treatment-naïve GI oncology, cardiovascular, and metabolic disease trial populations are accessed at scale across Chile's public research institutions.
Chile's most internationally connected medical school; consistently ranked among Latin America's top five medical faculties; and the academic anchor of Hospital UC Christus; the PUC Faculty of Medicine's research output spans oncology, cardiovascular medicine, metabolic disease, gastroenterology, and hepatology, with particular international visibility in GI oncology (including gallbladder cancer surgical outcomes research) and gastric cancer H. pylori eradication studies; PUC's international partnerships with US, European, and Australian medical centres have created the cross-border investigator relationships through which multinational Phase II–III programmes activate Chilean sites as part of global trial networks.
Chile's oldest public university and the academic anchor of the country's public hospital research network; Hospital Clínico, Hospital San Juan de Dios, Hospital Barros Luco-Trudeau, and other FONASA institutions; producing Chile's largest national volume of clinician investigators; the Universidad de Chile's biomedical research institutes (ICBM) and its oncology, haematology, hepatology, and pharmacology groups have generated internationally published clinical and translational research across Chile's most distinctive disease burdens; its public mission and FONASA affiliations make it the primary bridge between commercially sponsored Phase III programs and Chile's large treatment-naïve public patient populations.
The academic-clinical partnership anchoring Chile's most distinctively international private research environment; Clínica Alemana operating to German-comparable GCP standards, affiliated with the Universidad del Desarrollo Faculty of Medicine through the Clínica Alemana–UDD model; UDD produces Chilean investigators trained within Clínica Alemana's high-standard clinical environment, creating a pipeline pre-adapted to the documentation, protocol compliance, and pharmaceutical company relationship management that international Phase II–III sponsors expect; the Alemana–UDD model is Chile's most sophisticated private academic research partnership and the clearest embodiment of European medical research culture in a Latin American setting.
The academic anchor of the Biobío Region's clinical research network, affiliated with Hospital Regional de Concepción and other southern Chile academic institutions; Universidad de Concepción's Faculty of Medicine has been instrumental in building the oncology and pharmacology research infrastructure of southern Chile; the geographic corridor most directly relevant to Chile's gallbladder cancer patient populations; with established programmes in GI oncology, pharmacogenomics of Mapuche-ancestry populations, and rural health that provide the investigator community for commercially sponsored GI oncology trials in Concepción.
Global CRO with Chilean operations managing Phase II–IV programs across GI oncology (gallbladder and gastric cancer), cardiovascular, metabolic disease, CNS, and respiratory indications; ANAMED regulatory submission expertise and institutional CEC ethics navigation support; established site monitoring networks across Clínica Alemana, Hospital UC Christus, Clínica Las Condes, Hospital Clínico Universidad de Chile, and Hospital Sótero del Río; Pacific Alliance regional trial coordination pairing Chilean sites with Colombia, Peru, and Mexico within integrated Spanish-language Phase III networks.
International CRO with Chilean operations supporting Phase II–IV oncology, cardiovascular, and metabolic disease programs; established investigator relationships across Santiago's private and public academic hospital network; ANAMED regulatory strategy expertise for sponsors using Chile as the GI oncology or cardiovascular anchor of Pacific Alliance programmes; specialist GI oncology trial management reflecting Chile's gallbladder and gastric cancer research profile; Spanish-language documentation management and patient recruitment support across Santiago, Valparaíso, and Concepción.
International biopharmaceutical solutions company with Chilean operations providing integrated Phase I–IV clinical development services across oncology, cardiovascular, metabolic disease, and CNS indications; ANAMED submission expertise and institutional CEC ethics committee support; established site networks across Santiago's Clínica Alemana, Hospital UC Christus, and Clínica Las Condes private cluster alongside the Universidad de Chile public hospital network; Pacific Alliance regional programme management coordinating Chilean sites within Colombia-Peru-Mexico integrated Phase III designs for sponsors building Spanish-speaking Pacific Rim trial networks.
Chile's research pharmaceutical industry association; representing international pharmaceutical and biotechnology companies conducting clinical research in Chile; and the primary industry interface with ANAMED for clinical trial regulatory policy, CEC accreditation standards, and OECD pharmaceutical alignment commitments; CIF's annual Chilean clinical trial market statistics provide the data that sponsors use for feasibility assessment by therapeutic area and trial phase; its active engagement with ANAMED's regulatory modernisation programme has been central to the improving review timelines and GCP quality standards that have enhanced Chile's position as Latin America's quality benchmark for clinical research.
Chile is Latin America's quality benchmark for clinical research; a country of 19 million that punches far above its demographic weight through 15+ years of OECD-aligned regulatory standards, near-universal health insurance coverage creating structured patient pathways, a private research hospital cluster (Clínica Alemana, Hospital UC Christus, Clínica Las Condes) whose GCP documentation quality rivals European academic medical centres, and a gallbladder cancer disease burden that makes Chile the world's only viable platform for biliary oncology programs at Phase III scale. The gallbladder cancer argument is the series' starkest: no other country with OECD-aligned research infrastructure records gallbladder adenocarcinoma incidence at anything approaching Chilean levels, and no other country offers the combination of a 1.5–2 million-woman pre-malignant gallstone disease population, decades of published hepatopancreatobiliary surgical oncology research at Santiago's academic hospitals, and the Mapuche-ancestry patient catchment through southern Santiago's Sótero del Río and the Biobío corridor that Chile's geography provides. Beyond biliary oncology, Chile's gastric cancer burden, cardiovascular disease as leading mortality driver, and among LATAM's highest obesity and metabolic disease rates create a therapeutic portfolio broad enough to sustain a complete multi-indication Chilean Phase II–III programme, while ANAMED's 2020 regulatory reform and Clínica Alemana's German-standard research culture position Chile as the LATAM country whose research quality most closely approximates a Western European academic environment; and for sponsors building Pacific Alliance regional trial networks, Chile is the natural quality anchor pairing with Colombia, Peru, and Mexico within integrated Spanish-language Phase III programs across Latin America's most OECD-mature research corridor.
Keep exploring
Discover 11 early-phase clinical trials and design frameworks redefining development strategy in 2025-2026, and what sponsors can learn to reduce late-stage failure risk.
Four pervasive AI misconceptions in clinical trials that derail programs, inflate costs, and create regulatory exposure, with evidence on what the data actually shows.
Before selecting an AI patient screening tool for clinical trial recruitment, ask these 7 critical questions to avoid costly mismatches and protocol failures.
Accelerated Approval is an FDA pathway that allows earlier approval of drugs treating serious conditions and filling unmet medical need on the basis of a surrogate endpoint that is reasonably likely to predict clinical benefit, conditional on confirmatory post-marketing trials.